Prostate News and Research

RSS

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Cancer can be found earlier in high-risk men if more aggressive screening criteria used

Men at high risk of developing prostate cancer should undergo aggressive screening for the disease. That is the recommendation following a Fox Chase Cancer Center study of 520 men at high-risk of developing prostate cancer in which 25 percent were diagnosed with the disease despite having a low PSA. The findings were presented today at the American Society of Clinical Oncology 41st Annual Meeting.

15 May 2005

Breast cancer hormone drug might help prevent prostate cancer

A hormonal drug used to fight breast cancer might help prevent abnormal prostate growths from turning into cancers.

15 May 2005

Prostate cancer drug, Omnitarg by Genentech falls short

Research into an experimental prostate cancer drug being developed by Genentech Inc. will probably be abandoned after scientists found that the drug failed to prove effective in a mid-stage trial.

15 May 2005

New study says surgery still the best option for prostate cancer

A study by Swedish researchers has found that men who opt to have cancerous prostates surgically removed, have higher long-term survival rates than those who delay the operation, and the benefits of surgery may be greatest for men under 65.

11 May 2005

Discovery may pave way for immunotherapies for prostate cancer

Using a common chemotherapy agent, researchers at UCLA's Jonsson Cancer Center and the Department of Pathology and Laboratory Medicine found a way to move an important biomarker expressed in prostate cancer, shaking it loose from one location in a cell – where it could not be accessed by blood – to another, easier to target area.

11 May 2005

Cytogen Corporation and Dowpharma collaborate to create a targeted oncology product designed to treat prostate and other cancers

Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.

10 May 2005

Physical activity may reduce risk of prostate cancer

Men with higher levels of physical activity may reduce their risk of dying from prostate cancer and slow the progression of the disease, according to a study in the May 9 issue of Archives of Internal Medicine.

9 May 2005

Simple and efficient method for creation of novel protein functions in an existing protein scaffold

By designing a molecular bridge, scientists at the University of Illinois at Urbana-Champaign have forged a successful pathway through a complex ocean of barriers: They've changed the function of a protein using a co-evolution approach.

8 May 2005

New study confirms 'wait and see' approach best for some prostate cancers

Men diagnosed with low-grade localized prostate cancer who opt not to undergo aggressive treatment for the disease are unlikely to die of the disease, even after 20 years, according to researchers in Connecticut.

4 May 2005

Study examines influence of celebrity endorsements of cancer screening

More than one-half of adults surveyed nationwide had seen or heard celebrity endorsements of cancer screening tests, and more than one-fourth of those who had seen or heard an endorsement reported that it made them more likely to undergo the promoted screening test, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Long-term outcomes promising for patients with localized, low-grade prostate cancer

A study that includes 20 years of follow-up does not support aggressive treatment for localized, low-grade prostate cancer, with data indicating a small risk of progression of this grade of cancer, according to a study in the May 4 issue of JAMA.

3 May 2005

Researchers determine mechanism of action of chemotherapy drug motexafin gadolinium

The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.

1 May 2005

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

27 Apr 2005

New clinical trial focuses on quality of life for men with prostate cancer

A new Australian prostate cancer clinical trial hopes to provide clear evidence to men with prostate cancer about the best time to start hormone treatment in terms of prolonging life, balanced against the effects on their quality of life.

27 Apr 2005

Hereditary colorectal cancer risk lowered in those without certain gene defect

Families with a certain type of hereditary colorectal cancer have a reduced cancer risk if they do not have a gene defect found in many with this type of cancer risk, according to a study in the April 27 issue of JAMA.

26 Apr 2005

Smad7 protein levels may predict prostate cancer therapy response

Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).

23 Apr 2005

Inherited variations in mitochondrial DNA linked to renal and prostate cancer

More than 20 million men in the United States with a particular signature set of inherited characteristics and mutations in mitochondrial DNA (mtDNA) are at significantly increased risk for developing renal and prostate cancers, according to research at Emory University.

20 Apr 2005

Green tea appears to prevent cancer in men

After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.

20 Apr 2005

Selenium will have critical role in prostate cancer treatment

Researchers at Fox Chase Cancer Center in Philadelphia have come a step closer to understanding selenium's molecular role in causing prostate cancer cells to self-destruct. According to data presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif., selenium helps malignant cells overcome their resistance to TRAIL-induced apopstosis (self-inflicted cell death).

20 Apr 2005